COGSTATE LTD — Report Publication Announcement 2013

Jan 29, 2013

==> picture [114 x 101] intentionally omitted <==

ASX Announcement

Melbourne, Wednesday 30[th] January 2013

Advance Notice – 2013 Half-Year Results

CogState’s 2013 half-year results will be announced on Wednesday 20 February 2013.

An investor call will be held at 10.30am (AEST) following the release of the half-year results announcement. There will also be an opportunity for a question and answer session with Brad O’Connor, Chief Executive Officer.

Australian Participant Dial-In Numbers

Participants can dial either of the numbers below to join the call. They will need to quote ID 9389 1530.

Toll-free: 1800 123 296

Toll: + 61 2 8314 8370 - (can be used if dialing from international location)

International Participant Dial In Numbers

These numbers are toll-free dial in numbers for each country listed below. For countries not listed below, the Australian Toll number listed above can be dialed.

China 4001203085 Hong Kong 800 908 865 India 180030106141 Japan 0120 985 190 New Zealand 0800 452 782 Singapore 800 616 2288 United Kingdom 0808 234 0757 United States 1855 293 1544

For further information contact:

Kyahn Williamson Brad O’Connor Buchan Consulting CogState Chief Executive Officer +61 3 9866 4722 or 0401 018 828 +61 3 9664 1300 or 0411 888 347 kwilliamson@buchanwe.com.au boconnor@cogstate.com

About CogState

CogState Ltd (ASX: CGS) is a multi-faceted cognitive assessment and training company, focused on the development and commercialisation of rapid, computerised tests of cognition (brain function). It has three distinct business units:

Clinical Trials: In the clinical drug trial market, CogState technology and associated services are used by pharmaceutical and biotechnology companies to quantify the effect of drugs or other interventions on human subjects participating in clinical trials. Since sales into the clinical trials market began in 2004, CogState has secured agreements with top pharmaceutical companies including Pfizer, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Johnson & Johnson, Novartis, Lundbeck, Dainippon Sumitomo, Targacept, Otsuka, and Servier.

Axon Sports: The mission of Axon Sports is to “protect and train the athletic brain”. Axon’s focus is to research, develop and deliver cutting edge tools to assess, monitor and improve the athletic brain. Axon has been developing sport specific training products, initially focussed on American football and baseball, and the resulting technologies have now been launched within a small number of elite US college programs. In addition, the first of Axon’s consumer iPad apps was launched in 2012.

In the area of sports related concussion, CogState’s technology has been used by a number of highly regarded institutions and sporting organisations around the world for almost 10 years. That technology is now marketed to consumers as Axon Sports. Current users of CogState/Axon Sports in Australia include, the AFL and NRL, whilst in the USA elite programs such as the NBA, WNBA, NHL as well as college programs such as University of Notre Dame, University of Michigan and University of Connecticut all use the Axon Sports system.

Healthcare: CogState’s efforts in the Healthcare market are initially focussed on providing tools to primary care physicians (General Practitioners) to assess cognition in patients and allow physicians to identify subtle changes that could be indicative of the early stage of a neurodegenerative disease, such as Alzheimer’s disease. In June 2012, CogState entered into an agreement with Merck Canada Inc. providing it with the exclusive right to market and promote the technology (marketed as Cognigram) to primary care physicians in Canada. First sales from Cognigram will occur in January 2013.